Effect of Dapagliflozin on Patients With Heart Failure With and Without Diabetes
This exploratory analysis of a randomized trial examined the effect of dapagliflozin on a composite of worsening heart failure or cardiovascular death on individuals with heart failure with reduced ejection fraction with and without diabetes.
Source: JAMA - Journal of the American Medical Association - Category: General Medicine Source Type: research
More News: American Medical Association (AMA) | Cardiology | Cardiovascular | Dapagliflozin | Diabetes | Endocrinology | Forxiga | General Medicine | Heart | Heart Failure